Deepalakshmi Mani

Dr. Deepalakshmi Mani


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Tuberculosis
Verified
Journal Article
Closed access
RXRinu Mary Xavier
Rinu Mary Xavier
SSS.M. Sharumathi
S.M. Sharumathi
APArun Kanniyappan Parthasarathy
Arun Kanniyappan Parthasarathy
DMDeepalakshmi Mani
Deepalakshmi Mani
TMTharani Mohanasundaram
Tharani Mohanasundaram

27 May 2024 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
JSJ. Sabarish Sachithanandan
J. Sabarish Sachithanandan
DMDeepalakshmi Mani
Deepalakshmi Mani
HRH. Rajamohamed
H. Rajamohamed
PMPriscilla Mary
Priscilla Mary
MMM. Mohankumar
M. Mohankumar
SVS. Vikashini
S. Vikashini
Antimicrobial drug resistance within ESKAPE pathogens is a formidable global challenge, necessitating innovative solutions. This review explores a multifaceted strategy incorporating nanotechnology, CRISPR/Cas9, and other cutting-edge approaches to effectively combat multidrug resistance in ESKAPE bacteria. Nanotechnology presents a promising avenue through targeted drug delivery systems like antibiotic nanoparticles and antibiotic–antibody conjugates (AACs). While these nanostructures aim to enhance therapeutic efficacy and mitigate resistance spread, challenges such as anti-PEG antibodies and optimal drug release must be considered. Inspired by successful anticancer nanomedicines, nanotechnology seeks to optimize drug penetration and retention within infected tissues. The revolutionary CRISPR/Cas9 gene-editing technology offers a precise and tailored approach by selectively targeting and modifying bacterial resistance genes. This holds the potential to reverse or eliminate drug resistance in ESKAPE pathogens, though challenges like off-target effects and efficient delivery mechanisms require attention for clinical translation. Additionally, alternative approaches such as fecal microbial transplantation, bacteriophage therapy, and probiotic bacterial replacement are actively explored in clinical trials. These strategies diversify the arsenal against antibiotic resistance by targeting unique vulnerabilities in ESKAPE pathogens. A comprehensive and multidisciplinary strategy is imperative to effectively address antimicrobial drug resistance in ESKAPE pathogens. Integration of nanotechnology, CRISPR/Cas9, and emerging approaches offers a synergistic solution, holding promise in overcoming the challenges posed by these resilient multidrug-resistant bacteria. This review provides insights into current research, challenges, and potential breakthroughs, emphasizing the urgency for collaborative efforts to safeguard global health.

5 October 2025 in Annals of Neurosciences
Verified
Journal Article
Open access
BSBhavatharini Sukumaran
Bhavatharini Sukumaran
ASAswathy V S
Aswathy V S
RXRinu Mary Xavier
Rinu Mary Xavier
KMKishor M
Kishor M
SKSelvaraj Krishnamurthi
Selvaraj Krishnamurthi
DMDeepalakshmi Mani
Deepalakshmi Mani
Background: Genetic polymorphisms significantly influence individual responses to antidepressant medications. Among these, variations in the cytochrome P450 enzyme CYP2C19 , particularly the *2 allele, are known to affect drug metabolism, with implications for both efficacy and safety. South Indian populations exhibit a relatively high prevalence of this polymorphism, yet data specific to psychiatric cohorts remain limited. Purpose: This study aimed to determine the prevalence of the CYP2C19*2 polymorphism among South Indian psychiatric patients and to classify the corresponding metaboliser phenotypes to inform precision prescribing strategies for psychotropic medications. Methods: A cross-sectional observational study was conducted involving 140 psychiatric patients of South Indian ancestry across two tertiary psychiatric centres. Genomic DNA was extracted from peripheral blood samples and genotyped for the CYP2C19*2 (681G>A) variant using TaqMan-based real-time PCR. Participants were categorised into metaboliser phenotypes based on CPIC guidelines: normal (*1/*1), intermediate (*1/*2) and poor (*2/*2) metabolisers. Genotype frequencies were assessed for Hardy–Weinberg equilibrium (HWE) and descriptive statistics were used to summarise allele and phenotype distributions. Results: The CYP2C19*2 allele frequency was 27.5%. Genotype distribution was as follows: *1/*1 in 55.7%, *1/*2 in 33.6% and *2/*2 in 10.7% of participants. Accordingly, 44.3% of patients were classified as non-normal metabolisers (NMs) (intermediate or poor). The genotype distribution did not deviate significantly from HWE ( p = .0614), indicating population stability. Conclusion: A substantial proportion of South Indian psychiatric patients exhibit reduced CYP2C19 enzyme activity due to the presence of the *2 allele. These findings highlight the clinical utility of pre-emptive pharmacogenetic testing to guide antidepressant selection and dosing in this population, supporting the implementation of precision psychiatry in routine mental health care.

23 April 2022 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
DBDharini Boopathi
Dharini Boopathi
ASAkshatha J S
Akshatha J S
UBUma Buggi
Uma Buggi
HSHema Siva
Hema Siva
APArun K P
Arun K P
DMDeepalakshmi Mani
Deepalakshmi Mani
Background: Adverse Drug Reactions (ADR’s) to anti-TB drugs might contribute to the extension of treatment period, final termination, drug resistance and treatment failure as Anti-TB medications are the main stay treatment in Tuberculosis. These ADR’s may cause unintended interruption of treatment which may pose a challenge in TB management. Aim: This study aims to explore and observe adverse reactions of 1st line antitubercular drugs in DOTS treatment. Methodology: This is a analysis of ADRs of antitubercular drugs that were reported to ADR monitoring centre (AMC), SDSTRC and RGICD ,Bangalore either by spontaneous reporting or found by active surveillance methods. This study was for about 32 months. During this period all the ADRs caused by antitubercular drugs reported to the AMC were collected and classified based on WHO causality assessment. Later all those data were analyzed and results were generated Results: A total of 507 ADR’s were reported and out of which the majority of ADR’s were reported in adult population (45%). Based on gender, Male had a higher incidence of ADR (324, 63.9%). Based on WHO causality assessment scale, 69.4% of ADRs were ‘possible’ followed by 25.2% being ‘probable’ and 4.1% being ‘certain’. Conclusion: Monitoring of patients on Anti tubercular treatment with early identification and appropriate management of ADR becomes very essential. The timely and aggressive management of adverse effects of anti-tubercular drugs greatly facilitates patient adherence.

18 October 2025 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
NPNandini Prakash
Nandini Prakash
AKAdusumilli P Kumar
Adusumilli P Kumar
ARAruna C Ramesh
Aruna C Ramesh
DBDharini Boopathi
Dharini Boopathi
DMDeepalakshmi Mani
Deepalakshmi Mani
To investigate how well trigger tools function while evaluating adverse drug reactions (ADRs) among patients in emergency intensive care units (EICUs) and to assess the sensitivity of the Institute for Healthcare Improvement: Global Trigger Tool (IHI: GTT) for reporting adverse drug events among patients admitted to EICUs. A prospective, continuous, single-center research study was conducted for 9 months in the Department of Accident and Emergency Medicine. Triggers were defined based on the IHI GTT and Menat trigger tool. Each flagged case was reviewed for 15 minutes, which provides an equitable balance between efficiency and thoroughness to confirm the presence of an ADR. Performance metrics were calculated and analyzed. Three hundred medical records were collected, and 167 cases were randomly analyzed using 87 triggers. The prevalence of ADRs was 28%. The trigger tools showed 83.8% sensitivity and 48.7% specificity. The results indicated that the negative predictive value was 92.3%, while the positive predictive value was 72.9%. Trigger tools are a useful way to identify ADRs, even though issues with specificity and false positives still exist. Further improvements in technology and ongoing development will probably make these instruments even more effective and efficient in the dynamic environment of EICUs. Prakash N, Kumar AP, Ramesh AC, Boopathi D, Deepalaksmi M. Performance of Trigger Tools in Identifying Adverse Drug Events in Emergency Intensive Care Unit: A Prospective Observational Study. Indian J Crit Care Med 2025;29(10):861-864.

15 January 2026 in Drug Development Research
Verified
Journal Article
Closed access
BSBhavatharini Sukumaran
Bhavatharini Sukumaran
RXRinu Mary Xavier
Rinu Mary Xavier
AVAswathy Vs
Aswathy Vs
SSSharumathi Sm
Sharumathi Sm
RHRajamohamed H
Rajamohamed H
DMDeepalakshmi Mani
Deepalakshmi Mani